| Autor: |
Chantal F. Stockem, Sarah M. H. Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Dimitra R. Bakaloudi, Rafee Talukder, Belen Caramelo, Rafael Morales-Barrera, Astrid De Meulenaere, Alessandro Rametta, Andrea Bottelli, Felix Lefort, Patrizia Giannatempo, Christof Vulsteke, Joan Carles, Ignacio Duran, Petros Grivas, Alfonso Gómez de Liaño, Debbie G. J. Robbrecht, Begoña P. Valderrama, Vincent van der Noort, Michiel S. van der Heijden |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2731-9377 |
| DOI: |
10.1038/s44276-024-00104-3 |
| Popis: |
Abstract Background Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There is a need for prognostic factors, as these may help in the decision-making concerning anti-PD-(L)1 in patients with UC. Here, we examined long-term survival following anti-PD-(L)1 in advanced UC and assessed clinical factors for their correlation with survival. Methods We collected data from patients with advanced UC treated with anti-PD-(L)1 between 2013 and 2023. Overall- and progression-free survival (OS, PFS) were determined using the Kaplan-Meier method. Independent variables were analysed by uni- and multivariate Cox regression for their association with OS and PFS. Results Survival analyses included 552 patients. Patient characteristics in our cohort were consistent with those of a typical advanced UC population. After median follow-up of 49 months, five-year OS and PFS rates were 16.0% and 6.9% respectively. The absence of visceral and/or bone metastases and elevated C-reactive protein level, gamma-glutamyltransferase level and neutrophil-to-lymphocyte ratio were identified as favourable prognostic factors for OS. Conclusions A selected subset of patients with advanced UC may experience long-term clinical benefit from anti-PD-(L)1 treatment. We identified prognostic factors that might be used for risk assessment and clinical trial stratification. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink